Efficiency of afamin and fibroblast growth factor 21 for early prediction of gestational diabetes mellitus

Gestational diabetes mellitus (GDM) is among the most common complications during pregnancy. It is characterized by hyperglycemia that is first identified during pregnancy, typically in the second or third trimesters. However, the relatively late diagnosis limits timely glycemic control and preventive interventions. The present study aimed to evaluate the diagnostic potential of serum afamin and fibroblast growth factor 21 (FGF21) as early predictive biomarkers for GDM. The study involved 17 healthy pregnant women and 26 pregnant women with one or more risk factors for developing GDM. Fasting blood samples were collected in the 1st (8-12 weeks) and 2nd (22-28 weeks) trimesters of pregnancy. Higher serum afamin level was observed in GDM group at 1st trimester (92.9 ± 34.51 ng/ml) compared to normal pregnancy (57.1 ± 25.15 ng/ml). At 2nd trimester, no significant difference in circulated serum afamin was noted between the two groups (73.2 ± 20.30 ng/ml and 68.3 ± 18.74 ng/ml, for GDM and normal pregnancy, respectively). The study also indicated higher serum FGF21 in pregnancy complicated with GDM compared to normal pregnancy at both sampling times (1st trimester: 140.8 ± 32.83 and 97.1 ± 21.43 Pg/ml for GDM and normal; 2nd trimester: 123.8 ± 41.85 and 89.4 ± 32.53 Pg/ml for GDM and normal). At 1st trimester no significant correlations were noted between afamin and all parameters in normal pregnancy, however, in pregnancy complicated with GDM, positive correlations were noted between the hormone and the diabetic profile parameters and baby birth weight. At both 1st and 2nd trimesters, no correlation between FGF21 with all tested parameters, either in normal or complicated pregnancies. ROC curve analysis demonstrated that afamin (AUC = 0.826, P < 0.001), FGF21 (AUC = 0.877, P < 0.001), and their combined assessment (AUC = 0.9, P < 0.001) were strong predictors of GDM development at 1st trimester before the development of the disease than expectant mothers with normal pregnancy.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-05-11
DOI
https://doi.org/10.1038/s41598-026-51453-7
Primary Topic
Fibroblast Growth Factor Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficiency of afamin and fibroblast growth factor 21 for early prediction of gestational diabetes mellitus

Amani F. H. Noureldeen, Eman H. A. Hemida, Mostafa M. Elhady, Radwa M. M. Zaki et al.
Scientific Reports
Fibroblast Growth Factor Research
article

Efficiency of afamin and fibroblast growth factor 21 for early prediction of gestational diabetes mellitus

Amani F. H. Noureldeen, Eman H. A. Hemida, Mostafa M. Elhady, Radwa M. M. Zaki, Abdelrahman O. Sabri
article en

Abstract

Gestational diabetes mellitus (GDM) is among the most common complications during pregnancy. It is characterized by hyperglycemia that is first identified during pregnancy, typically in the second or third trimesters. However, the relatively late diagnosis limits timely glycemic control and preventive interventions. The present study aimed to evaluate the diagnostic potential of serum afamin and fibroblast growth factor 21 (FGF21) as early predictive biomarkers for GDM. The study involved 17 healthy pregnant women and 26 pregnant women with one or more risk factors for developing GDM. Fasting blood samples were collected in the 1st (8-12 weeks) and 2nd (22-28 weeks) trimesters of pregnancy. Higher serum afamin level was observed in GDM group at 1st trimester (92.9 ± 34.51 ng/ml) compared to normal pregnancy (57.1 ± 25.15 ng/ml). At 2nd trimester, no significant difference in circulated serum afamin was noted between the two groups (73.2 ± 20.30 ng/ml and 68.3 ± 18.74 ng/ml, for GDM and normal pregnancy, respectively). The study also indicated higher serum FGF21 in pregnancy complicated with GDM compared to normal pregnancy at both sampling times (1st trimester: 140.8 ± 32.83 and 97.1 ± 21.43 Pg/ml for GDM and normal; 2nd trimester: 123.8 ± 41.85 and 89.4 ± 32.53 Pg/ml for GDM and normal). At 1st trimester no significant correlations were noted between afamin and all parameters in normal pregnancy, however, in pregnancy complicated with GDM, positive correlations were noted between the hormone and the diabetic profile parameters and baby birth weight. At both 1st and 2nd trimesters, no correlation between FGF21 with all tested parameters, either in normal or complicated pregnancies. ROC curve analysis demonstrated that afamin (AUC = 0.826, P < 0.001), FGF21 (AUC = 0.877, P < 0.001), and their combined assessment (AUC = 0.9, P < 0.001) were strong predictors of GDM development at 1st trimester before the development of the disease than expectant mothers with normal pregnancy.

Scientific ReportsVol. 16(1)
Ain Shams University (EG), Ain Shams University Hospital (EG)
Ain Shams University, Science and Technology Development Fund
Good health and well-being
Openalex Percentile: Top 9%
Fibroblast Growth Factor Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.